Literature DB >> 10636490

HTLV-I specific IFN-gamma+ CD8+ lymphocytes correlate with the proviral load in peripheral blood of infected individuals.

R Kubota1, T Kawanishi, H Matsubara, A Manns, S Jacobson.   

Abstract

Human T lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is an inflammatory neurological disease caused by HTLV-I infection. It has been shown that HAM/TSP patients have high proviral loads and an extraordinarily high frequency of circulating CD8 + cytotoxic T lymphocytes specific for HTLV-I in their peripheral blood when compared to asymptomatic HTLV-I carriers (AC). We have previously described an intracellular cytokine detection assay, in which interferon-gamma (IFN-gamma) + CD8 + lymphocytes are specific for HTLV-I in infected individuals. Here, we have established a competitive polymerase chain reaction assay to measure the proviral load of patients and investigate a potential relationship between proviral load and virus-specific CD8 + lymphocytes. Genomic DNA was extracted from peripheral blood lymphocytes (PBL) from eight HAM/TSP patients and seven AC for the measurement of HTLV-I measuring proviral loads. The same PBL were analyzed for intracellular IFN-gamma expression by flow cytometry. In the HAM/TSP patients and AC, the average proviral loads were 34,482 and 9784 copy/microg DNA (P = 0.021), and the average of IFN-gamma + CD8 + lymphocytes in total PBL were 1.47 and 0.08% (P = 0.001), respectively. It was confirmed that HAM/TSP patients have both high proviral loads and increased HTLV-I-specific CD8 + lymphocytes. Furthermore, we found a positive correlation between both factors in the patients with HAM/TSP (P = 0.044) but not in the AC (P = 0.508). These findings suggest that the high number of HTLV-I-specific lymphocytes may result from the increased proviral load in HAM/TSP patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10636490     DOI: 10.1016/s0165-5728(99)00175-7

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  31 in total

Review 1.  Neuroimmunity of HTLV-I Infection.

Authors:  Eiji Matsuura; Yoshihisa Yamano; Steven Jacobson
Journal:  J Neuroimmune Pharmacol       Date:  2010-05-02       Impact factor: 4.147

2.  Deregulated expression of CD40 ligand in HTLV-I infection: distinct mechanisms of downregulation in HTLV-I-transformed cell lines and ATL patients.

Authors:  Nicole S Harhaj; Branislava Janic; Juan C Ramos; William J Harrington; Edward W Harhaj
Journal:  Virology       Date:  2007-01-26       Impact factor: 3.616

3.  Quantitative differences in HTLV-I antibody responses: classification and relative risk assessment for asymptomatic carriers and ATL and HAM/TSP patients from Jamaica.

Authors:  Yoshimi Enose-Akahata; Anna Abrams; Kory R Johnson; Elizabeth M Maloney; Steven Jacobson
Journal:  Blood       Date:  2012-02-07       Impact factor: 22.113

4.  IL-10 produced by CD4+ and CD8+ T cells emerge as a putative immunoregulatory mechanism to counterbalance the monocyte-derived TNF-alpha and guarantee asymptomatic clinical status during chronic HTLV-I infection.

Authors:  G E A Brito-Melo; V Peruhype-Magalhães; A Teixeira-Carvalho; E F Barbosa-Stancioli; A B F Carneiro-Proietti; B Catalan-Soares; J G Ribas; O A Martins-Filho
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

5.  Presentation of human T cell leukemia virus type 1 (HTLV-1) Tax protein by dendritic cells: the underlying mechanism of HTLV-1-associated neuroinflammatory disease.

Authors:  Sharrón L Manuel; Todd D Schell; Edward Acheampong; Saifur Rahman; Zafar K Khan; Pooja Jain
Journal:  J Leukoc Biol       Date:  2009-08-05       Impact factor: 4.962

Review 6.  Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases.

Authors:  Denise Utsch Gonçalves; Fernando Augusto Proietti; João Gabriel Ramos Ribas; Marcelo Grossi Araújo; Sônia Regina Pinheiro; Antônio Carlos Guedes; Anna Bárbara F Carneiro-Proietti
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

7.  In vivo selection of T-cell receptor junctional region sequences by HLA-A2 human T-cell lymphotropic virus type 1 Tax11-19 peptide complexes.

Authors:  M Saito; G P Taylor; A Saito; Y Furukawa; K Usuku; J N Weber; M Osame; C R Bangham
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

8.  High expression of CD244 and SAP regulated CD8 T cell responses of patients with HTLV-I associated neurologic disease.

Authors:  Yoshimi Enose-Akahata; Eiji Matsuura; Unsong Oh; Steven Jacobson
Journal:  PLoS Pathog       Date:  2009-12-04       Impact factor: 6.823

9.  HLA class I binding of HBZ determines outcome in HTLV-1 infection.

Authors:  Aidan Macnamara; Aileen Rowan; Silva Hilburn; Ulrich Kadolsky; Hiroshi Fujiwara; Koichiro Suemori; Masaki Yasukawa; Graham Taylor; Charles R M Bangham; Becca Asquith
Journal:  PLoS Pathog       Date:  2010-09-23       Impact factor: 6.823

10.  Stable ubiquitination of human T-cell leukemia virus type 1 tax is required for proteasome binding.

Authors:  Estelle Chiari; Isabelle Lamsoul; Julie Lodewick; Cécile Chopin; Françoise Bex; Claudine Pique
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.